

Author(s):
Question: Sotrovimab compared to no treatment for Hospitalization/Respiratory failure/ICU/Mortality reduction
Setting:
Bibliography:

Certainty assessment							N _e of patients		Effect		Certainty	Importance
N _s of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Sotrovimab	no treatment	Relative (95% CI)	Absolute (95% CI)		
Hospitalization												
6	non-randomised studies	not serious	not serious	not serious	not serious	none	222/6567 (3.4%)	22745/545335 (4.2%)	RR 0.71 (0.54 to 0.93)	12 fewer per 1,000 (from 19 fewer to 3 fewer)	 Low	
Respiratory failure												
3	non-randomised studies	not serious	not serious	not serious	not serious	none	9/1650 (0.5%)	51/3850 (1.3%)	RR 0.37 (0.19 to 0.76)	8 fewer per 1,000 (from 11 fewer to 3 fewer)	 Low	
ICU												
3	non-randomised studies	not serious	not serious	not serious	not serious	none	4/1617 (0.2%)	27/3786 (0.7%)	RR 0.40 (0.15 to 1.04)	4 fewer per 1,000 (from 6 fewer to 0 fewer)	 Low	
Mortality												
6	non-randomised studies	not serious	not serious	not serious	not serious	none	10/6567 (0.2%)	2829/545330 (0.5%)	RR 0.34 (0.19 to 0.61)	3 fewer per 1,000 (from 4 fewer to 2 fewer)	 Low	

CI: confidence interval; RR: risk ratio